WitrynaHERTHENA-Lung02 (NCT05338970) is a global, open-label, randomized, phase III trial evaluating the efficacy and safety of HER3-DXd vs PBC in pts (≈560) with metastatic … Witryna19 cze 2024 · Patritumab Deruxtecan Under Exploration in Phase 2 HERTHENA-Lung01 Trial for EGFR+ NSCLC. The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously …

第一三共 中国 > 新闻资讯

Witryna3 sie 2024 · HERTHENA-Lung01 is a randomized, open-label trial that will enroll approximately 420 patients with metastatic or locally advanced NSCLC harboring an activating EGFR mutation. Witryna1 wrz 2024 · Request PDF On Sep 1, 2024, T.S.K. Mok and others published 1195TiP HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or ... council oak preschool round rock

Co to jest hernia hiatus oesophagei? Kliniki.pl

Witryna22 lut 2024 · HERTHENA-Lung02. Medable Inc. 10+ Downloads. Everyone. info. Install. Add to wishlist. About this app. arrow_forward. This app is specifically intended for study participants in the Daiichi … WitrynaAbout HERTHENA-Lung01 HERTHENA-Lung01 is a global, multicenter, open-label, phase 2 study evaluating the safety and efficacy of patritumab deruxtecan in patients with locally advanced or metastatic NSCLC with an EGFR-activating mutation (exon 19 deletion or L858R) who have progressed after receiving at least one EGFR TKI and at Witryna23 gru 2024 · HERTHENA-Lung01, a pivotal phase 2 study in patients with loc ally advanced or metastatic EGFR-mutated NSCLC previously treated with a TKI and platinum -based chemotherapy; a phase 1/2 study in HER3 expressing metastatic breast cancer; a phase 1 study in combination with osimertinib in council oak ac menu